Umecrine Cognition AB Presents Preclinical Data on Golexanolone

Umecrine Cognition AB will present new preclinical data for golexanolone, demonstrating motor and non-motor benefits in an alpha-synuclein Parkinson's disease model. The presentation will take place at MJFF's PDTC 2026 and an invitation-only showcase.